Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:DEPO
CUSIP24990810
Phone510-744-8000
Debt
Debt-to-Equity Ratio2.48
Current Ratio0.55
Quick Ratio0.53
Price-To-Earnings
Trailing P/E Ratio-5.79
Forward P/E Ratio-15.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$380.72 million
Price / Sales1.23
Cash Flow$0.8459 per share
Price / Cash8.63
Book Value$2.69 per share
Price / Book2.71
Profitability
EPS (Most Recent Fiscal Year)($1.26)
Net Income$-102,490,000.00
Net Margins-9.52%
Return on Equity-13.22%
Return on Assets-2.52%
Miscellaneous
Employees434
Outstanding Shares63,920,000
Market Cap$461.47 million
Depomed (NASDAQ:DEPO) Frequently Asked Questions
What is Depomed's stock symbol?
Depomed trades on the NASDAQ under the ticker symbol "DEPO."
How were Depomed's earnings last quarter?
Depomed Inc (NASDAQ:DEPO) released its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company had revenue of $63.27 million for the quarter, compared to analysts' expectations of $63.72 million. Depomed had a negative net margin of 9.52% and a negative return on equity of 13.22%. The company's revenue for the quarter was down 37.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 EPS. View Depomed's Earnings History.
When is Depomed's next earnings date?
What price target have analysts set for DEPO?
7 brokerages have issued 12-month target prices for Depomed's stock. Their forecasts range from $7.00 to $10.00. On average, they expect Depomed's share price to reach $8.6667 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Depomed.
What is the consensus analysts' recommendation for Depomed?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Depomed.
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include Clovis Oncology (CLVS), Enanta Pharmaceuticals (ENTA), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Nabriva Therapeutics (NBRV), Insmed (INSM), Puma Biotechnology (PBYI), Reata Pharmaceuticals (RETA), Aimmune Therapeutics (AIMT), Allakos (ALLK), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), ARMO Biosciences (ARMO), Amneal Pharmaceuticals (AMRX) and Arrowhead Pharmaceuticals (ARWR).
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
- Mr. August J. Moretti, CFO & Sr. VP (Age 67)
- Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
- Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
- Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)
Has Depomed been receiving favorable news coverage?
Media stories about DEPO stock have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Depomed earned a coverage optimism score of 0.12 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 48.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Depomed.
Who are Depomed's major shareholders?
Depomed's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.15%), Dimensional Fund Advisors LP (5.26%), Connor Clark & Lunn Investment Management Ltd. (4.52%), STARBOARD VALUE LP (4.30%), Starboard Value LP (2.51%) and Millennium Management LLC (2.21%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.
Which institutional investors are selling Depomed stock?
DEPO stock was sold by a variety of institutional investors in the last quarter, including Starboard Value LP, State of Wisconsin Investment Board, Deltec Asset Management LLC, State Board of Administration of Florida Retirement System, Engineers Gate Manager LP, Schwab Charles Investment Management Inc., Mackay Shields LLC and Alps Advisors Inc.. View Insider Buying and Selling for Depomed.
Which institutional investors are buying Depomed stock?
DEPO stock was purchased by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Renaissance Technologies LLC, American Century Companies Inc., Millennium Management LLC, Bank of Montreal Can, Acadian Asset Management LLC, GSA Capital Partners LLP and SG Americas Securities LLC. View Insider Buying and Selling for Depomed.
How do I buy shares of Depomed?
Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Depomed's stock price today?
One share of DEPO stock can currently be purchased for approximately $7.30.
How big of a company is Depomed?
Depomed has a market capitalization of $461.47 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.
How can I contact Depomed?
Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]
MarketBeat Community Rating for Depomed (NASDAQ DEPO)
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
